$0.70
0.46%
Nasdaq, Jul 03, 08:08 pm CET
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Cue Biopharma, Inc. Stock price

$0.70
+0.06 10.05% 1M
-0.69 49.99% 6M
-0.39 36.22% YTD
-0.28 29.06% 1Y
-1.75 71.62% 3Y
-22.19 96.96% 5Y
-10.93 94.02% 10Y
-10.93 94.02% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+0.00 0.46%
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Key metrics

Basic
Market capitalization
$52.4m
Enterprise Value
$42.6m
Net debt
positive
Cash
$13.1m
Shares outstanding
61.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.6 | 6.4
EV/Sales
5.3 | 5.2
EV/FCF
negative
P/B
6.6
Financial Health
Equity Ratio
54.4%
Return on Equity
-232.4%
ROCE
-609.3%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$8.0m | $8.2m
EBITDA
$-40.7m | -
EBIT
$-41.1m | $-40.4m
Net Income
$-40.6m | $-36.8m
Free Cash Flow
$-34.9m
Growth (TTM | estimate)
Revenue
13.8% | -12.2%
EBITDA
20.1% | -
EBIT
20.0%
Net Income
18.8% | 9.4%
Free Cash Flow
10.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-509.7% | -
EBIT
-514.7%
Net
-507.9% | -451.7%
Free Cash Flow
-436.5%
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
1.1%
Employees
41
Rev per Employee
$230.0k
Show more

Is Cue Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Cue Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cue Biopharma, Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Cue Biopharma, Inc. forecast:

Buy
83%
Hold
17%

Financial data from Cue Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.99 7.99
14% 14%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
13% 13%
182%
- Research and Development Expense 35 35
16% 16%
434%
-41 -41
20% 20%
-510%
- Depreciation and Amortization 0.40 0.40
17% 17%
5%
EBIT (Operating Income) EBIT -41 -41
20% 20%
-515%
Net Profit -41 -41
19% 19%
-508%

In millions USD.

Don't miss a Thing! We will send you all news about Cue Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cue Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months
Neutral
GlobeNewsWire
13 days ago
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2
Neutral
GlobeNewsWire
about 2 months ago
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments
More Cue Biopharma, Inc. News

Company Profile

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Daniel Passeri
Employees 41
Founded 2014
Website www.cuebiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today